Smoking is known to worsen thyroid eye disease (TED), and according to a new study, it may worsen the response to treatment with teprotumumab.
In this single-center, retrospective cohort study, patients with type 2 TED who started or completed therapy during the data collection period had a reduction in clinical activity score, diplopia, and proptosis evaluated.
No significant difference was found between smokers and non-smokers at baseline, however, after treatment, there was a statistically significant difference in proptosis reduction between the groups.
Reference
O’Dell JM, Mussatto CC, Chu RL, Al-Sabbagh MQ, Timoney PJ, Sokol JA. Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study. Kans J Med. 2023 Mar 15;16:62-64. doi: 10.17161/kjm.vol16.18940. PMID: 36970041; PMCID: PMC10035644.
Related Content
